1. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
- Author
-
Pawan Kumar Raghav, Zoya Mann, Simran Kaur Ahluwalia, and Raja Rajalingam
- Subjects
Clinical Trials and Supportive Activities ,Drug repurposing ,Peptidyl-Dipeptidase A ,Vaccine Related ,Clinical trials ,Clinical Research ,Biodefense ,Humans ,Pharmacology & Pharmacy ,Lung ,Pharmacology ,Vaccines ,SARS-CoV-2 ,Prevention ,Drug Repositioning ,COVID-19 ,Pneumonia ,Pharmacology and Pharmaceutical Sciences ,COVID-19 Drug Treatment ,Infectious Diseases ,Emerging Infectious Diseases ,Good Health and Well Being ,5.1 Pharmaceuticals ,Pneumonia & Influenza ,Molecular Medicine ,Immunization ,Development of treatments and therapeutic interventions ,Infection ,Protein Binding - Abstract
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection is caused when Spike-protein (S-protein) present on the surface of SARS-CoV-2 interacts with human cell surface receptor, Angiotensin-converting enzyme 2 (ACE2). This binding facilitates SARS-CoV-2 genome entry into the human cells, which in turn causes infection. Since the beginning of the pandemic, many different therapies have been developed to combat COVID-19, including treatment and prevention. This review is focused on the currently adapted and certain other potential therapies for COVID-19 treatment, which include drug repurposing, vaccines and drug-free therapies. The efficacy of various treatment options is constantly being tested through clinical trials and in vivo studies before they are made medically available to the public. more...
- Published
- 2023
- Full Text
- View/download PDF